LINC01389: A Potential Drug Target and Biomarker (G102724077)

Target Name: LINC01389

NCBI ID: G102724077

LINC01389

Other Name(s): Long intergenic non-protein coding RNA 1389 | long intergenic non-protein coding RNA 1389

LINC01389: A Potential Drug Target and Biomarker

LINC01389 is a long intergenic non-protein coding RNA (lncRNA) with a length of approximately 290 nucleotides. It is found in various tissues and cell types of the human body, including the brain, heart, liver, and muscle. LINC01389 has been identified as a potential drug target and biomarker due to its unique structure, expression pattern, and involvement in various cellular processes.

Structure and Expression

The structure of LINC01389 is unique because it is composed of a long non-coding RNA molecule that is predominantly transcribed from the 5' end. The 5' end of the RNA molecule contains a unique G-Crich sequence, which is highly conserved across various species, indicating that LINC01389 may have originated from a common ancestor gene.

Expression patterns of LINC01389 are highly variable between different cell types and tissues. For example, LINC01389 is highly expressed in the brain, where it is predominantly transcribed from the 5' end. It is also expressed in other tissues, such as the heart, liver, and muscle, where it is transcribed from the 3' end. The expression patterns of LINC01389 may be regulated by various factors, including gene expression networks, DNA binding proteins, and RNA binding proteins.

Drug Target Potential

The unique structure and expression patterns of LINC01389 make it an attractive drug target. LINC01389 has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation. It is also involved in the regulation of cellular signaling pathways, such as the NF-kappa pathway.

LINC01389 has been shown to interact with several protein kinases, including TGK1, TPK1, and FAK. These interactions may regulate various cellular processes, including cell signaling pathways, cell adhesion, and migration. Therefore, LINC01389 may be a potential drug target for therapies targeting these pathways.

Biomarker Potential

The expression patterns of LINC01389 may be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. LINC01389 has been shown to be highly expressed in several types of cancer, including breast, ovarian, and colorectal cancer.

In addition, LINC01389 has been shown to be involved in the regulation of cellular signaling pathways that are implicated in various neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Therefore, LINC01389 may be a potential biomarker for these diseases.

Conclusion

LINC01389 is a unique and promising RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and expression patterns, as well as its involvement in various cellular processes, make it an attractive target for therapies targeting these processes. Further research is needed to determine the functional consequences of LINC01389, as well as its potential as a biomarker for various diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 1389

The "LINC01389 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01389 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets